ENTA
Enanta Pharmaceuticals, Inc. [ENTA] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
ENTA Stock Summary
Top 10 Correlated ETFs
ENTA
Top 10 Correlated Stocks
ENTA
In the News
ENTA Financial details
Company Rating
Sell
Market Cap
348.02M
Income
-138.24M
Revenue
73.62M
Book val./share
9.1
Cash/share
15.99
Dividend
-
Dividend %
-
Employees
145
Optionable
No
Shortable
Yes
Earnings
06 May 2024
P/E
-1.86
Forward P/E
-
PEG
-1.69
P/S
3.16
P/B
1.15
P/C
0.83
P/FCF
-2.23
Quick Ratio
6.52
Current Ratio
6.73
Debt / Equity
0.13
LT Debt / Equity
0.11
-
-
EPS (TTM)
-6.56
EPS next Y
-
EPS next Q
-
EPS this Y
7.95%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
NAN%
Revenue last 5Y
-17.34%
Revenue Q/Q
-4.91%
EPS Q/Q
18.8%
-
-
-
-
SMA20
7.14%
SMA50
25%
SMA100
66.67%
Inst Own
68.35%
Inst Trans
0.72%
ROA
-29%
ROE
-52%
ROC
-0.34%
Gross Margin
100%
Oper. Margin
-173%
Profit Margin
-169%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
8.08-38.79
52W High
-65.08%
52W Low
+65.88%
RSI
36
Rel Volume
0.45
Avg Volume
251.28K
Volume
114.08K
Perf Week
-19.77%
Perf Month
-15.59%
Perf Quarter
57.23%
Perf Half Y
37.09%
-
-
-
-
Beta
0.488
-
-
Volatility
1.28%, 1.21%
Prev Close
-5.21%
Price
13.27
Change
-13.44%
ENTA Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-09-30
| Metric | History | 2019-09-30 | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 10.48 | 6.14 | 4.81 | 4.18 | 3.78 | |
| Net income per share | 2.37 | -1.81 | -3.92 | -5.91 | -6.38 | |
| Operating cash flow per share | 3.65 | 0.36 | -3.47 | -4.12 | -4.92 | |
| Free cash flow per share | 3.37 | 0.28 | -3.51 | -4.22 | -5.35 | |
| Cash per share | 17.12 | 19.39 | 12.1 | 12.1 | 17.64 | |
| Book value per share | 23.62 | 22.85 | 19.8 | 15.6 | 10.34 | |
| Tangible book value per share | 23.62 | 22.85 | 19.8 | 15.6 | 10.34 | |
| Share holders equity per share | 23.62 | 22.85 | 19.8 | 15.6 | 10.34 | |
| Interest debt per share | 0.46 | 0.41 | 0.26 | 1.3 | 1.51 | |
| Market cap | 1.18B | 912.85M | 1.15B | 1.07B | 234.22M | |
| Enterprise value | 1.13B | 833.82M | 1.09B | 1.05B | 175.35M | |
| P/E ratio | 25.37 | -25.24 | -14.51 | -8.78 | -1.75 | |
| Price to sales ratio | 5.73 | 7.45 | 11.8 | 12.4 | 2.96 | |
| POCF ratio | 16.47 | 128.79 | -16.37 | -12.61 | -2.27 | |
| PFCF ratio | 17.83 | 161.77 | -16.2 | -12.3 | -2.09 | |
| P/B Ratio | 2.54 | 2 | 2.87 | 3.33 | 1.08 | |
| PTB ratio | 2.54 | 2 | 2.87 | 3.33 | 1.08 | |
| EV to sales | 5.49 | 6.81 | 11.27 | 12.19 | 2.21 | |
| Enterprise value over EBITDA | 30.64 | -20.03 | -9.98 | -8.68 | -1.42 | |
| EV to operating cash flow | 15.76 | 117.64 | -15.63 | -12.38 | -1.7 | |
| EV to free cash flow | 17.05 | 147.76 | -15.46 | -12.08 | -1.56 | |
| Earnings yield | 0.04 | -0.04 | -0.07 | -0.11 | -0.57 | |
| Free cash flow yield | 0.06 | 0.01 | -0.06 | -0.08 | -0.48 | |
| Debt to equity | 0 | 0.02 | 0.01 | 0.08 | 0.12 | |
| Debt to assets | 0 | 0.02 | 0.01 | 0.07 | 0.06 | |
| Net debt to EBITDA | -1.39 | 1.9 | 0.47 | 0.15 | 0.48 | |
| Current ratio | 17.77 | 18.08 | 8.82 | 10.45 | 6.73 | |
| Interest coverage | 4.17 | 0 | 0 | -78.73 | -26.65 | |
| Income quality | 1.54 | -0.2 | 0.89 | 0.7 | 0.77 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0.06 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.13 | 0.22 | 0.34 | 0.53 | 0.67 | |
| Research and developement to revenue | 0.69 | 1.12 | 1.79 | 1.91 | 2.06 | |
| Intangibles to total assets | 0 | 0 | 0 | -0.01 | -0.02 | |
| Capex to operating cash flow | -0.08 | -0.2 | 0.01 | 0.03 | 0.09 | |
| Capex to revenue | -0.03 | -0.01 | -0.01 | -0.02 | -0.11 | |
| Capex to depreciation | -1.66 | -0.4 | -0.22 | -0.71 | -3.82 | |
| Stock based compensation to revenue | 0.09 | 0.16 | 0.22 | 0.31 | 0.36 | |
| Graham number | 35.47 | 30.54 | 41.77 | 45.54 | 38.52 | |
| ROIC | 0.08 | -0.09 | -0.2 | -0.33 | -0.52 | |
| Return on tangible assets | 0.09 | -0.07 | -0.18 | -0.32 | -0.28 | |
| Graham Net | 17.69 | 18.74 | 11.48 | 11.26 | 7.35 | |
| Working capital | 379.24M | 412.68M | 282.85M | 281.89M | 360M | |
| Tangible asset value | 462.49M | 455.58M | 401.5M | 326.51M | 228.27M | |
| Net current asset value | 374.51M | 406.29M | 279.66M | 257.64M | 177.25M | |
| Invested capital | 0 | 0.02 | 0.01 | 0.08 | 0.12 | |
| Average receivables | 59.26M | 37.4M | 42.16M | 54.93M | 44.33M | |
| Average payables | 5.72M | 6.21M | 7.64M | 7.77M | 5.05M | |
| Average inventory | 0 | 0 | -18.63M | -18.63M | 0 | |
| Days sales outstanding | 91.27 | 70.01 | 228.73 | 207.73 | 182.57 | |
| Days payables outstanding | 0 | 0 | 0 | 736.63 | 630.71 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 4 | 5.21 | 1.6 | 1.76 | 2 | |
| Payables turnover | 0 | 0 | 0 | 0.5 | 0.58 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | 0.1 | -0.08 | -0.2 | -0.38 | -0.62 | |
| Capex per share | -0.28 | -0.07 | -0.04 | -0.1 | -0.43 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q1
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 1.13 | 0.85 | 0.9 | 0.9 | 0.85 | |
| Net income per share | -1.39 | -1.79 | -1.86 | -1.33 | -1.58 | |
| Operating cash flow per share | -1.71 | -0.66 | -1.53 | -1.03 | -1.18 | |
| Free cash flow per share | -1.86 | -0.77 | -1.63 | -1.09 | -1.22 | |
| Cash per share | 10.3 | 9.99 | 18.36 | 17.57 | 15.99 | |
| Book value per share | 14.45 | 12.81 | 11.3 | 10.29 | 9.1 | |
| Tangible book value per share | 14.45 | 12.81 | 11.3 | 10.29 | 9.1 | |
| Share holders equity per share | 14.45 | 12.81 | 11.3 | 10.29 | 9.1 | |
| Interest debt per share | 1.15 | 1.22 | 1.22 | 1.41 | 1.37 | |
| Market cap | 968.36M | 850.66M | 450.56M | 235.21M | 198.44M | |
| Enterprise value | 951.48M | 805.47M | 383.08M | 176.33M | 184M | |
| P/E ratio | -8.35 | -5.65 | -2.88 | -2.09 | -1.49 | |
| Price to sales ratio | 41.06 | 47.8 | 23.85 | 12.42 | 11.02 | |
| POCF ratio | -27.17 | -61.72 | -14.02 | -10.89 | -7.94 | |
| PFCF ratio | -24.96 | -52.62 | -13.14 | -10.24 | -7.7 | |
| P/B Ratio | 3.22 | 3.16 | 1.89 | 1.09 | 1.03 | |
| PTB ratio | 3.22 | 3.16 | 1.89 | 1.09 | 1.03 | |
| EV to sales | 40.34 | 45.26 | 20.28 | 9.31 | 10.22 | |
| Enterprise value over EBITDA | -31.7 | -20.42 | -10.43 | -6.86 | -6.14 | |
| EV to operating cash flow | -26.7 | -58.44 | -11.92 | -8.16 | -7.36 | |
| EV to free cash flow | -24.52 | -49.83 | -11.18 | -7.68 | -7.14 | |
| Earnings yield | -0.03 | -0.04 | -0.09 | -0.12 | -0.17 | |
| Free cash flow yield | -0.04 | -0.02 | -0.08 | -0.1 | -0.13 | |
| Debt to equity | 0.08 | 0.1 | 0.12 | 0.12 | 0.13 | |
| Debt to assets | 0.07 | 0.09 | 0.06 | 0.06 | 0.06 | |
| Net debt to EBITDA | 0.56 | 1.15 | 1.84 | 2.29 | 0.48 | |
| Current ratio | 12.33 | 8.43 | 6.58 | 6.73 | 6.25 | |
| Interest coverage | 19.96 | 16.6 | 18.38 | -9.85 | -10.14 | |
| Income quality | 1.23 | 0.37 | 0.82 | 0.77 | 0.75 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.54 | 0.77 | 0.67 | 0.73 | 0.92 | |
| Research and developement to revenue | 1.73 | 2.44 | 2.28 | 1.91 | 2.02 | |
| Intangibles to total assets | 0 | 0 | 0 | -0.02 | 0 | |
| Capex to operating cash flow | 0.09 | 0.17 | 0.07 | 0.06 | 0.03 | |
| Capex to revenue | -0.13 | -0.13 | -0.11 | -0.07 | -0.04 | |
| Capex to depreciation | -6.18 | -4.41 | -3.3 | -2.04 | -1.23 | |
| Stock based compensation to revenue | 0.3 | 0.41 | 0.37 | 0.35 | 0.45 | |
| Graham number | 21.28 | 22.71 | 21.72 | 17.58 | 18.01 | |
| ROIC | -0.09 | -0.12 | -0.14 | -0.11 | -0.14 | |
| Return on tangible assets | -0.08 | -0.12 | -0.08 | -0.06 | -0.08 | |
| Graham Net | 9.91 | 8.93 | 7.73 | 7.32 | 6.19 | |
| Working capital | 260.7M | 238.97M | 380.28M | 360M | 327.9M | |
| Tangible asset value | 300.84M | 269.38M | 237.82M | 228.27M | 191.88M | |
| Net current asset value | 237.01M | 214.07M | 191.12M | 177.25M | 153.69M | |
| Invested capital | 0.08 | 0.1 | 0.12 | 0.12 | 0.13 | |
| Average receivables | 50.16M | 48.93M | 45.69M | 42.21M | 39.76M | |
| Average payables | 5.18M | 8.06M | 9.85M | 6.01M | 6.71M | |
| Average inventory | 0.5 | 1 | 1 | 0.5 | 0 | |
| Days sales outstanding | 195.71 | 235.53 | 213.47 | 188.34 | 199.5 | |
| Days payables outstanding | 766.5 | 1.96K | 1.1K | 551.17 | 1.31K | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0.46 | 0.38 | 0.42 | 0.48 | 0.45 | |
| Payables turnover | 0.12 | 0.05 | 0.08 | 0.16 | 0.07 | |
| Inventory turnover | 511K | 540K | 651K | 0 | 0 | |
| ROE | -0.1 | -0.14 | -0.16 | -0.13 | -0.17 | |
| Capex per share | -0.15 | -0.11 | -0.1 | -0.06 | -0.04 |
ENTA Frequently Asked Questions
What is Enanta Pharmaceuticals, Inc. stock symbol ?
Enanta Pharmaceuticals, Inc. is a US stock , located in Watertown of Ma and trading under the symbol ENTA
What is Enanta Pharmaceuticals, Inc. stock quote today ?
Enanta Pharmaceuticals, Inc. stock price is $13.27 today.
Is Enanta Pharmaceuticals, Inc. stock public?
Yes, Enanta Pharmaceuticals, Inc. is a publicly traded company.
Company Profile
- Volume Average 251.28K
- Market Capitalization 348.02M
- Employee 145
- CEO Dr. Jay R. Luly Ph.D.
- Headquarters Watertown,MA,US
- IPO Date 2013-03-21
-
Website
https://www.enanta.com 
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.
